BEDFORD — Shares of Anika Therapeutics Inc. skidded lower Wednesday after the company said the Food and Drug Administration upheld its decision against approving the company’s osteoarthritis treatment Monovisc. The company said it will schedule a meeting with the FDA to determine its next steps. Monovisc is designed to treat pain in patients suffering from osteoarthritis of the knee.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help